Case number 1:23-cv-00699
Celgene Corporation et al v. MSN Laboratories Private Limited et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Feb 29, 2024 | N/A | CASE CLOSED per entry of Consent Judgment and Order of Dismissal in lead case number 21-1795-JLH. (ceg) (Entered: 02/29/2024) (0) |
| Feb 29, 2024 | 15 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,846,628 B2; US 11,571,436 B2. (Attachments: # 1 Consent Judgment)(ceg) (Entered: 02/29/2024) (0) |
| Feb 28, 2024 | N/A | CORRECTING ENTRY: D.I. 15 has been removed from the docket. All filings are to be made in the lead case (C.A. No. 21-1795) only. (ceg) (Entered: 02/28/2024) (0) |
| Jan 16, 2024 | N/A | Case Reassigned to Judge Jennifer L. Hall. Please include the initials of the Judge (JLH) after the case number on all documents filed. Associated Cases: 1:21-cv-01795-RGA, 1:23-cv-00699-RGA, 1:23-cv-01008-RGA, 1:23-cv-01019-RGA(nms) (Entered: 01/16/2024) (0) |
| Aug 31, 2023 | 13 | Letter to The Honorable Richard G. Andrews, from Michael J. Farnan, regarding 30 month stay. (Farnan, Michael) Modified on 8/31/2023 (nms). (Entered: 08/31/2023) (1) |
| Aug 31, 2023 | 14 | SO ORDERED Granting (D.I. 9 in 23-cv-699-RGA; D.I. 61 in 21-cv-1795-RGA) Stipulation and Proposed Order to Consolidate and Modify Scheduling Order (*Reset Deadlines/Hearings: Fact Discovery completed by 1/31/2024; a 3-day Bench Trial will start on 9/23/2024, at 8:30 AM in Courtroom 6A; a Pretrial Conference is set for 9/13/2024, at 9:00 AM in Courtroom 6A) (see Order for further details). Signed by Judge Richard G. Andrews on 8/31/2023. Associated Cases: 1:21-cv-01795-RGA, 1:23-cv-00699-RGA(nms) (Entered: 08/31/2023) (6) |
| Aug 30, 2023 | 12 | ORAL ORDER: The parties are to submit a joint letter advising whether there is/are 30 month stays and whether moving the trial date will impact the possibility of the need for emergency relief. Ordered by Judge Richard G. Andrews on 8/30/2023. Associated Cases: 1:21-cv-01795-RGA, 1:23-cv-00699-RGA(nms) (Entered: 08/30/2023) (0) |
| Aug 28, 2023 | 10 | ANSWER to 1 Complaint and COUNTERCLAIMS against all Plaintiffs, by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Stamoulis, Stamatios) Modified on 8/29/2023 (nms). (Entered: 08/28/2023) (30) |
| Aug 28, 2023 | 11 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent MSN Private Limited for MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc. filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc.. (Stamoulis, Stamatios) (Entered: 08/28/2023) (2) |
| Aug 25, 2023 | N/A | Pro Hac Vice Attorney Amy K. Wigmore, Gerard A. Salvatore, Heather M. Petruzzi, Nora Q.E. Passamaneck, Andrew J. Danford, and Li-tsung A. Chen for Celgene Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mkr) (Entered: 08/25/2023) (0) |
| Aug 25, 2023 | N/A | Pro Hac Vice Attorney David Mlaver for Celgene Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 08/25/2023) (0) |
| Aug 24, 2023 | 9 | STIPULATION and [Proposed] Order to Consolidate and Modify Scheduling Order by Bristol-Myers Squibb Company, Celgene Corporation, Celgene International Sarl. (Attachments: # 1 Exhibit A)(Farnan, Brian) (Entered: 08/24/2023) (0) |
| Aug 23, 2023 | 8 | MOTION for Pro Hac Vice Appearance of Attorney Amy K. Wigmore, Heather M. Petruzzi, Andrew J. Danford, Nora Q.E. Passamaneck, David Mlaver, Gerard A. Salvatore, and Li-jsung Alyssa Chen - filed by Bristol-Myers Squibb Company, Celgene Corporation, Celgene International Sarl. (Farnan, Michael) (Entered: 08/23/2023) (9) |
| Aug 23, 2023 | N/A | SO ORDERED, re 8 MOTION for Pro Hac Vice Appearance of Attorney Amy K. Wigmore, Heather M. Petruzzi, Andrew J. Danford, Nora Q.E. Passamaneck, David Mlaver, Gerard A. Salvatore, and Li-jsung Alyssa Chen, filed by Celgene Corporation, Celgene International Sarl, Bristol-Myers Squibb Company. Signed by Judge Richard G. Andrews on 8/23/2023. (nms) (Entered: 08/23/2023) (0) |
| Jul 6, 2023 | 7 | STIPULATION TO EXTEND TIME to answer, move, or otherwise respond to the Complaint to 8/28/2023 - filed by Bristol-Myers Squibb Company, Celgene Corporation, Celgene International Sarl. (Farnan, Michael) (Entered: 07/06/2023) (2) |
| Jul 6, 2023 | N/A | SO ORDERED, re 7 Stipulation and Proposed Order to Extend Time (*Reset Answer Deadlines: MSN Laboratories Private Limited answer due 8/28/2023; MSN Pharmaceuticals, Inc. answer due 8/28/2023). Signed by Judge Richard G. Andrews on 7/6/2023. (nms) (Entered: 07/06/2023) (0) |
| Jul 5, 2023 | N/A | Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) (Entered: 07/05/2023) (0) |
| Jun 27, 2023 | 1 | Complaint* (1) |
| Jun 27, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jdb) (Entered: 06/27/2023) (3) |
| Jun 27, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 05/18/2023. Date of Expiration of Patent: 05/14/2029 and 06/03/2030.Thirty Month Stay Deadline: 11/18/2025. (jdb) (Entered: 06/27/2023) (2) |
| Jun 27, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,846,628 B2; 11,571,436 B2. (jdb) (Entered: 06/27/2023) (1) |
| Jun 27, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Bristol-Myers Squibb Company and Corporate Parent Celgene Corporation for Celgene International Sarl; Corporate Parent Bristol-Myers Squibb Company for Celgene Corporation filed by Bristol-Myers Squibb Company, Celgene Corporation, Celgene International Sarl. (jdb) (Entered: 06/27/2023) (2) |
| Jun 27, 2023 | 6 | Summons Issued as to MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc. on 6/27/2023. (jdb) (Entered: 06/27/2023) (4) |
